D

Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?

Retrieved on: 
Thursday, December 21, 2023
Annual report, Post office box, Vertex Pharmaceuticals, Novo Nordisk, Investment, Capital, Intuitive Surgical, Diabetes, CRISPR Therapeutics, Montreux Healthcare Fund, SIX Swiss Exchange, ChatGPT, Acquisition, Artificial intelligence, Health care, Lux, Growth, AI, Grand Canal Dock, Eli Lilly, Economics, Judgement, Risk, University of Zurich, Clinical trial, AG, House, CNMV, Prospectus, Biotechnology, Hematology, Thermo Fisher Scientific, Doctor of Philosophy, DNA, Genome, Roche, History, Therapy, Failure, Health, D, Patient, Obesity, CHF, Medtech, South, TEL, Harmony Row, Research, SICAV, University, Federal Executive Boards, News, DSM-IV codes, Pharmaceutical industry, Medical device, Cryptocurrency, Libre, Amgen

Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?

Key Points: 
  • Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?
  • In his investment outlook for 2024, Cyrill Zimmermann, a member of Bellevue Asset Management’s Executive Board and Head of Healthcare Funds & Mandates, explains why it is probably only a matter of time before healthcare stocks are rediscovered by the wider investment community.
  • In view of this dynamic situation, Bellevue Asset Management launched Bellevue Obesity Solutions in November, a fund that invests in the most attractive companies across the entire value chain for obesity treatment and management.
  • Dr. Cyrill Zimmermann is Head of Healthcare Funds & Mandates and a member of the Executive Board of Bellevue Asset Management.

Iveco Group: periodic report on the buyback program

Retrieved on: 
Monday, November 20, 2023
IVECO, Agriculture, EXM, FPT Industrial, IDV, ASTRA, IVG, Iveco, D, Share repurchase, Online shopping, Transport

An overall overview of the purchases carried out under the current share buyback program as well as the details of the above transactions, are available on the Company’s corporate website at the following address: https://www.ivecogroup.com/investors/stock_information/share_buyback .

Key Points: 
  • An overall overview of the purchases carried out under the current share buyback program as well as the details of the above transactions, are available on the Company’s corporate website at the following address: https://www.ivecogroup.com/investors/stock_information/share_buyback .
  • Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society.
  • Iveco Group employs more than 35,000 people around the world and has 20 industrial sites and 29 R&D centres.
  • Further information is available on the Company’s website www.ivecogroup.com

IVECO concludes its biggest investment cycle ever with the launch of a completely renewed product and service offering

Retrieved on: 
Thursday, November 16, 2023
Agriculture, IDV, Safety, IVG, D, Iveco, Artificial intelligence, Advanced driver-assistance system, EXM, CO2, FPT Industrial, History, Insurance, Social responsibility, Algorithm, Ecosystem, IVECO, ASTRA, Natural gas, Iveco S-Way, Partnership, ADAS, Leg, Green, GATE, Mobile phone, Renewable energy, Cursor, Metallica

For the first time in its history, the brand has renewed every single product line in its entire range at the same time with the conclusion of its biggest investment ever: 1 billion euros.

Key Points: 
  • For the first time in its history, the brand has renewed every single product line in its entire range at the same time with the conclusion of its biggest investment ever: 1 billion euros.
  • Today, around 100,000 IVECO vehicles are connected, and the ambition is to reach half a million by 2030.
  • To close the launch event, a special announcement was made about a partnership between IVECO and rock legends Metallica.
  • Iveco Group employs more than 35,000 people around the world and has 20 industrial sites and 29 R&D centres.

Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

Retrieved on: 
Wednesday, November 15, 2023
Abele, GMP, Senior, D, Head, Commercial, Dishman Carbogen Amcis, Doctor of Philosophy, API, Organic, QUVIVIQ, ETH Zurich, HAE, University, Hereditary angioedema, CMC, Actelion, Active ingredient, University of Konstanz, Production, Chemistry, Idorsia

ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer.

Key Points: 
  • ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer.
  • In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development.
  • Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities, GMP manufacturing, global vendor management, and people leadership.
  • “Stefan joins Pharvaris at a transformative time as we prepare to transition into a late-stage clinical company and prepare for commercialization in the coming years,” said Berndt Modig, Chief Executive Officer of Pharvaris.

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe

Retrieved on: 
Wednesday, November 15, 2023
Brain, Research, D, Clinical trial, Patient, White matter, Alzheimer's disease, Phase, MRI, Biomarker, CTA, Inflammation, Health insurance

Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company dedicated to  advancing treatments that leverage the patient’s innate immune system to combat disease, has received acceptance of a Clinical Trial Application (CTA) under EU Clinical Trials Regulation to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™ in Poland. Additional regulatory approval for the Phase II AD clinical trial is expected from at least two to potentially six more EU countries in the upcoming months.  The EU approval is part of the Company’s international clinical development strategy for XPro™ in patients with early AD. The trial is currently enrolling patients in Australia, Canada, and the United Kingdom.

Key Points: 
  • Additional regulatory approval for the Phase II AD clinical trial is expected from at least two to potentially six more EU countries in the upcoming months.
  • The EU approval is part of the Company’s international clinical development strategy for XPro™ in patients with early AD.
  • The Phase II clinical trial is a global, multi-center, randomized clinical study in patients diagnosed with early Alzheimer's disease who have biomarkers of elevated inflammation.
  • In a prior Phase I open-label trial, INmune Bio met all primary and secondary endpoints.

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Retrieved on: 
Tuesday, November 14, 2023
Accounting, Safety, D, Platinum, Carcinoma, Sonifi Solutions, CFO, Patient, Investment, Research, IPO, Financial management, Hand, Amgen, Pharmaceutical industry, Genelux Corporation

WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates.
  • R&D Expenses: Research and development expenses were $2.8 million for the third quarter of 2023, as compared to $2.4 million for the third quarter of 2022.
  • G&A Expenses: General and administrative expenses were $2.5 million for the third quarter of 2023, as compared to $2.2 million for the third quarter of 2022.
  • Net Loss: Net loss was $5.3 million for the third quarter of 2023, as compared to net income of $4.9 million for the third quarter of 2022.

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Retrieved on: 
Tuesday, November 14, 2023
Imatinib, Safety, D, Parkinson's disease, Therapy, International, IND, PD, Clinical trial, Patient, Research, European, Multiple system atrophy, MSA, FDA, Tyrosine kinase inhibitor, Federal, Orphan, ABL, Pharmaceutical industry

“We are very pleased with the progress of the last quarter,” noted Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase.

Key Points: 
  • “We are very pleased with the progress of the last quarter,” noted Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase.
  • Twenty-four participants have been enrolled, 7 prospective participants are in screening and 15 potential participants are going through informed consents.
  • The 201 Trial patient portal ( www.the201trial.com ) has been visited by more than 20,000 unique people since launch in September, 2023.
  • The Company expects that existing cash and cash equivalents will be sufficient to fund operations into the fourth quarter of 2024.

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, November 14, 2023
Structure, Safety, SAN, D, Investment, Research, Obesity, Therapy, Growth, GPCR, Weight loss, Pharmaceutical industry, T2DM

SAN FRANCISCO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the third quarter ended September 30, 2023, and highlighted recent corporate achievements.

Key Points: 
  • “Our recent Phase 1b data support the potential of GSBR-1290 as a promising, differentiated oral GLP-1 receptor agonist with once-daily dosing,” said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics.
  • GSBR-1290 demonstrated significant weight loss of up to 4.9% (placebo-adjusted) supporting once-daily dosing, and an encouraging safety profile with no adverse event-related discontinuations.
  • In preparation for these studies, Structure has initiated a formulation bridging study to evaluate a tablet formulation of GSBR-1290.
  • R&D Expenses: Research and development expenses were $17.5 million for the quarter ended September 30, 2023, as compared to $9.2 million for the same period in 2022.

KULR Technology Group Reports Third Quarter 2023 Financial Results; Company on Track with Analysts’ Q4 Forecasts

Retrieved on: 
Tuesday, November 14, 2023
Lithium, NYSE, SAN, UAV, D, CFO, Recycling, Vibration, Canter and gallop, KULR, Administration, NASA, Strategic partnership, SUV, Manufacturing, Partnership, Operating cost, R, Research and development, Growth, Suretrack Contracts Services, National Aeronautic Association, Holocene, Transport, Video game, Cryptocurrency, Research

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a global leader in sustainable energy management, today reported results for the third quarter ended September 30, 2023.

Key Points: 
  • SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a global leader in sustainable energy management, today reported results for the third quarter ended September 30, 2023.
  • Cash and Accounts Receivable: As of September 30, 2023, the Company had cash and accounts receivable combined of $2.46 million.
  • Gross Margins: Gross margin was 44% in the quarter ending September 30, 2023, compared to 33% in the same period last year.
  • Selling, General and Administrative (SG&A) Expenses: SG&A expenses increased to $4.79 million in the third quarter of 2023 from $4.35 million in the same period last year.

ProKidney Reports Third Quarter Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Chronic kidney disease, Webcast, Research, D, International, Biostatistics, Patient, Clinical trial, CKD, Conference, REACT, Pharmaceutical industry, Cryptocurrency

WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023.
  • Further, you may listen to the presentation by dialing 1-877-407-0784 (US) or 1-201-689-8560 (International) and entering the Conference ID: 13742672.
  • Following the completion of the presentation, a replay of the webcast will also be accessible on the investor relations section of ProKidney website here .
  • Shares outstanding: Class A and Class B ordinary shares outstanding at September 30, 2023 totaled 235,434,630.